Cilgavimab/Tixagevimab

Cilgavimab/Tixagevimab is a combination of two monoclonal antibodies designed for the prevention and treatment of COVID-19. This combination is developed by AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company.

Mechanism of Action

Cilgavimab and Tixagevimab work together to bind to different sites on the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells. This dual action is believed to increase the effectiveness of the treatment and reduce the likelihood of the virus developing resistance.

Clinical Trials

The combination of Cilgavimab and Tixagevimab has been tested in several clinical trials. In the Phase III trials, the combination was shown to reduce the risk of severe COVID-19 and death in high-risk patients.

Approval

As of February 2022, Cilgavimab/Tixagevimab has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA) and conditional marketing authorization by the European Medicines Agency (EMA).

Side Effects

Common side effects of Cilgavimab/Tixagevimab include nausea, vomiting, diarrhea, and fever. Serious side effects are rare but can include severe allergic reactions.

See Also

• COVID-19 treatment
• Monoclonal antibodies
• AstraZeneca

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian